Related Experiment Video

Updated: May 19, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Juvenile dermatomyositis: new insights and new treatment strategies

Neil Martin, Charles K Li, Lucy R Wedderburn

    Therapeutic Advances in Musculoskeletal Disease
    |August 8, 2012
    PubMed

    Insights

    Juvenile dermatomyositis (JDM) is a rare childhood autoimmune disease affecting muscles and skin. Research is advancing understanding of its causes, complications, and new treatment strategies for affected children.

    Area of Science:

    • Pediatric Rheumatology
    • Autoimmune Diseases
    • Dermatology

    Background:

    • Juvenile dermatomyositis (JDM) is a rare, serious autoimmune condition in children impacting muscles and skin.
    • The exact cause of JDM is unknown, but genetic and environmental factors are implicated.
    • Children with JDM often experience severe complications like skin ulceration, calcinosis, gut vasculopathy, and central nervous system issues, differing from adult dermatomyositis.

    Purpose of the Study:

    • To review recent advancements in understanding the pathogenesis of JDM.
    • To discuss current methods for assessing disease activity and severity in pediatric patients.
    • To outline modern therapeutic approaches and ongoing clinical trials for JDM.

    Main Methods:

    • Literature review of recent studies on JDM.
    • Analysis of clinical trial data and treatment outcomes.
    • Synthesis of current knowledge on JDM pathogenesis and assessment.

    Main Results:

    • Recent insights into JDM pathogenesis are emerging.
    • Standardized assessment tools are crucial for effective disease management.
    • International multicenter trials are evaluating novel JDM treatments.

    Conclusions:

    • Understanding JDM pathogenesis is key to developing targeted therapies.
    • A comprehensive approach to assessment aids in managing JDM complications.
    • New treatments are becoming available, offering hope for improved outcomes in children with JDM.

    Keywords:
    dermatomyositisidiopathic inflammatory muscle diseasejuvenilemyopathy

    Related Concept Videos

    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
    Nephrotic Syndrome II : Assessment and Medical Management01:26

    Nephrotic Syndrome II : Assessment and Medical Management

    IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    Changes in Skin Color: Clinical Perspectives01:14

    Changes in Skin Color: Clinical Perspectives

    The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
    Albinism
    Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
    Asthma: Pathogenesis and Management01:20

    Asthma: Pathogenesis and Management

    Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
    Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.